miRNa signature in small extracellular vesicles and their association with platinum resistance and cancer recurrence in ovarian cancer

Mona Alharbi, Shayna Sharma, Dominic Guanzon, Andrew Lai, Felipe Zuñiga, Muhammad J.A. Shiddiky, Yusuke Yamauchi, Alexis Salas-Burgos, Yaowu He, Tanja Pejovic, Carmen Winters, Terry Morgan, Lewis Perrin, John D. Hooper, Carlos Salomon

Research output: Contribution to journalArticlepeer-review

42 Citations (Scopus)

Abstract

Carboplatin, administered as a single drug or in combination with paclitaxel, is the standard chemotherapy treatment for patients with ovarian cancer (OVCA). Recent evidence suggests that miRNAs associated with small extracellular vesicles (sEVs) participate in the development of chemoresistance. We studied the effect of carboplatin in a heterogeneity population of OVCA cells and their derived sEVs to identify mechanisms associated with chemoresistance. sEVs were quantified using an engineered superparamagnetic material, gold-loaded ferric oxide nanotubes and a screen-printed electrode. miR-21-3p, miR-21-5p, and miR-891-5p are enriched in sEVs, and they contribute to carboplatin resistance in OVCA. Using a quantitative MS/MS, miR-21-5p activates glycolysis and increases the expression of ATP-binding cassette family and a detoxification enzyme. miR-21-3p and miR-891-5p increase the expression of proteins involved in DNA repair mechanisms. Interestingly, the levels of miR-891-5p within sEVs are significantly higher in patients at risk of ovarian cancer relapse. Identification of miRNAs in sEVs also provides the opportunity to track them in biological fluids to potentially determine patient response to chemotherapy.

Original languageEnglish
Article number102207
Number of pages17
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume28
Early online date23 Apr 2020
DOIs
Publication statusPublished - Aug 2020

Fingerprint

Dive into the research topics of 'miRNa signature in small extracellular vesicles and their association with platinum resistance and cancer recurrence in ovarian cancer'. Together they form a unique fingerprint.

Cite this